Regulatory Science Symposium: Diversity in Clinical Trials in the Time of COVID-19 Session 3: FDA Initiatives to Address Diversity in Clinical Trials

Tagged: clinical trials, academia, clinical research, diversity, inclusion, fda, guidances, regulations, nih, barriers to patient access

NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.